RNA-based antibacterial agents: Mechanisms, functional insights, and challenges in therapeutic development

Basit Öğe Kaydı
dc.authorid0000-0003-4056-1673
dc.contributor.authorAbavisani, Mohammad
dc.contributor.authorSajjadi, Seyed Mohammad
dc.contributor.authorEbadpour, Negar
dc.contributor.authorKesharwani, Prashant
dc.contributor.authorKarav, Sercan
dc.contributor.authorSahebkar, Amirhossein
dc.date.accessioned2026-02-03T12:02:47Z
dc.date.available2026-02-03T12:02:47Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAntibacterial resistance is a vivified worldwide problem of health care. RNA-based antibacterial agents, on the other hand, present a new method of using mechanisms such as RNA interference (RNAi), riboswitch regulation, clustered regularly interspaced short palindromic repeats (CRISPR)- CRISPR-associated protein (Cas) systems, and antisense oligonucleotides (ASOs) to the max. CRISPR-Cas systems allow opportunity to cure targeted region of a resistant gene or cut it out completely, which is a highly adaptable method for treating multidrug-resistant (MDR) bacteria. ASOs, along with peptide nucleic acids (PNAs) and phosphorodiamidate morpholino oligomers (PMOs), are substances that stop bacterial gene expression, thus, minimizing the pathogenicity. Nevertheless, their promise is put down because of problems such as delivery efficiency, molecular stability, and off-target effects that come with these. Innovations in chemical changes and delivery technologies have resulted in the development of the stable and targeted delivery of RNA-based agents. This study takes a close look at the mechanisms, therapeutic potential, and challenges of RNA-based antibacterials and stresses their ability to be the most successful tools in combating antibiotic resistance. The combination of these strategies with the existing antibiotics could increase their efficacy, make it possible for us to address resistance and open new ways for antibacterial therapies.
dc.identifier.doi10.1016/j.cej.2025.165777
dc.identifier.issn1385-8947
dc.identifier.issn1873-3212
dc.identifier.scopus2-s2.0-105010681708
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.cej.2025.165777
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34869
dc.identifier.volume520
dc.identifier.wosWOS:001548547900007
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier Science Sa
dc.relation.ispartofChemical Engineering Journal
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectCRISPR-Cas systems
dc.subjectDrug resistance
dc.subjectmicrobial
dc.subjectOligonucleotides
dc.subjectAntisense
dc.subjectRNA interference
dc.titleRNA-based antibacterial agents: Mechanisms, functional insights, and challenges in therapeutic development
dc.typeReview

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu